Updated: 07/23/2014 6:14 PM
Created: 07/23/2014 6:13 PM WDIO.com
WASHINGTON (AP) - The Food and Drug Administration has approved a new combination pain pill from the maker of OxyContin that is designed to discourage abuse by painkiller addicts.
Purdue Pharma's new drug Targiniq ER is an extended release tablet that combines oxycodone - the active ingredient in OxyContin - with the drug naloxone. FDA regulators approved the drug for daily, round-the-clock pain that does not respond to other medications.
If abusers crush the tablets for snorting or injecting naloxone blocks the euphoric effects of oxycodone, making the drug more difficult to abuse. Naloxone is currently used to reverse the overdose effects of opioids, highly addictive painkilling drugs including morphine, methadone, codeine and others.
The FDA notes that Targiniq can still be abused by simply swallowing the tablets, the most frequent method of painkiller abuse.
The FDA has been under intense public pressure to combat the national epidemic of prescription opioid abuse. Deaths linked to addictive medications like OxyContin and Vicodin have quadrupled since 1990 to an estimated 16,500 in 2010, the most recent year for which the Centers for Disease Control and Prevention reports figures.
Doctors prescribe opioids for a wide range of ailments, from post-surgical pain to arthritis and migraines.
Stamford, Connecticut-based Purdue has often been cited by public health advocates as a key contributor to the overprescribing of opioids. In 2007, Purdue Pharma and three of its executives paid $634 million and pleaded guilty to charges of misleading the public about the safety and addictiveness of OxyContin.
Since then the company introduced a harder-to-abuse version of OxyContin that is designed to resist crushing, chewing and dissolving.
"The FDA is committed to combatting the misuse and abuse of all opioids, and the development of opioids that are harder to abuse is needed in order to help address the public health crisis of prescription drug abuse in the U.S.," said FDA's Dr. Sharon Hertz.
The FDA is requiring Purdue to conduct long-term follow-up studies tracking rates of abuse, addiction, overdose and death with Targiniq. Those requirements are standard for all extended release opioid drugs approved in the U.S.
(Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.)
Ice Caves to Reopen Thursday Morning
After a short closure, the Apostle Islands National Lakeshore says they will be reopening the ice caves to the public at 7 a.m. Thursday.
Spring Ice Breaking Postponed in the Twin Ports
The U.S. Coast Guard Cutter Alder was scheduled to start ice breaking operations on Wednesday, but a public information officer tells Eyewitness News that date has been postponed. He said they will probably go out next week or a little later.
State Bound Hounds: Duluth East Honors Hockey, Robotics, Diver
With three state championships and 22 tournament appearances under their belt, the Duluth East boys hockey team is used to being in the spotlight, but Wednesday, they were happy to share that with a handful of other state-bound hounds.
Go Red For Women: Challengers Have Success
Women who've taken a heart health makeover challenge have lost weight, reduced stress, and lowered their cholesterol levels. And it was time to celebrate them on Wednesday.
7 Minneapolis Gang Members Indicted on Crack Cocaine Charges
A federal grand jury has indicted alleged members of the Taliban gang and the Young N Thuggin gang for conspiring to distribute crack cocaine in Duluth, St. Cloud and the Twin Cities.